Lineage Cell Therapeutics, Inc. · AMEX:LCTX
Lineage Cell Therapeutics — Biotime — Shareholder Meeting (June 2017)
19 slides from Lineage Cell Therapeutics's shareholder meeting presentation, Jun 29, 2017
Slide 1: Update on BioTime's Subsidiary AgeX Therapeutics
eos = BIOTIME Leading the Regenerative Medicine Revolution NYSE MKT: BTX Update on BioTime’s a Subsidiary AgeX Therapeutics Annual Meeting of Shareholders June 29, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not
Slide 3: Pluripotency: Telomeres as a Clocking Mechanism
Pluripotency Telomeres as a Clocking Mechanism beets Population Doublings Germ-Line 22 34 43 55 65 72 82 90 — Crelomerase +) 2 \ Somatic hy s 10 Ne (Telomerase -) Hil 8 3 4 rs . i g2 5 \ 3 3 = gs Neonatal Hayflick Limit Age BIOTIME
Slide 4: Pluripotency
Pluripotency * Scalable source of all human cell types * Immortal cells allow sophisticated genetic modifications * Regen phenotype * = BIOTIME
Slide 5: 2nd Generation - Universal PureStem Technology
2™4 Generation - Universal PureStem™ Technology seoserelUC SOOCSOCUC SO ss Se . os A oe = =e wet 2 > ee 2 — > we" oss if i a Hy => => => £ Purification of EScells Problem of impurities H y 2 r il H -€ PureStem = >200-old diversity 3 Scalable, monoctonally- 3 purified regenerative progenitors IOTIME
Slide 6: Planned Product Focus
Planned Product Fo + AgeX consolidates certain early-stage assets and research outside of BioTime’s current three core areas of ophthalmology, aesthetics, and delivery. + Our objective in forming AgeX is to find a way to unlock the potential value of these non-core assets for our existing shareholde
Slide 7: Brown Adipose Cells Regulate Metabolism
Brow! ipose Cells Regulate Metabolis| Maintenance WAT S Weight Gain INS, q %, T2 Diabetes BIOTIME
Slide 8: Brown Adipose Cells Regulate Metabolism
Brown Adipose Cells Regulate Metaboli Brown Adipose Tissue Activity (PET-CT with "F-FDG) Lean, Lean, Overweight, Thermoneutral Cold Exposure Cold Exposure ‘ate 90408" sos >= foe Obesity (2011) 19, 1785-1760, éoi:10.1038/oby 2011.125, BIOTIME
Slide 9: Brown Adipose Cells Regulate Metabolism
ipose Cells Regulate Metabolis New Powers of Brown Fat: Fighting the Metabolic Syndrome Jan Nedergaard,* Tore Bengtsson,’ and Barbara Cannon’ “Tne Wenner Gren Insfute, Stockrolm University, Stockholm 10691, Sweden “Correspondence: jar@metabolsuse DOI 10. 1016/j emer 2011 c2.000 Reversal of Type 1 Di
Slide 10: Industrially-Scalable AgeX-BAT1
Industrially-Scalable Agex-BAT1 Stained for Brown Adipocyte Marker UCP1 Tissue-Sourced Brown Adipocytes PureStem Brown Adipocytes = BIOTIME
Slide 11: Obesity/T2D Market/Competition
Obesity/T2D Market/Competition * 30M Americans have diabetes! 1:3 Americans will have diabetes by 2050 * The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%, according to business in
Slide 12: Ischemia Program: AGEX-VASC1
Ischemia Program: AGEX-VASC1 Regenerative Vascular Progenitors Monoclonal Endothelial Cells 100% Purity An} coat aPC Gale (Primal Bia ler) + Highly scalable with high purity & potency + Extensive IP estate + Formulated in a proprietary matrix with good safety profile for human lipotransfer = = BIOTI
Slide 13: Cardiovascular Market
Cardiovascular Market > STrillion Market Worldwide American American Heart | Stroke Association | Association is why 41) http://www.heart.org/idc/eroups /heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf BIOTIME
Slide 14: Induced Tissue Regeneration (iTR)
ed Tissue Regeneration (iTR) Repair > Breakdown Repair = Breakdown Breakdown > Repair Embryonic m= Fetal-Adult ===> Aging Adult Highly Regenerative Limited Regeneration Non-Regenerative Construction Maintenance Destruction { nduced Tissue Regeneration | BIOTIME
Slide 15: Telomerase & iTR
Telo se&iTR Animals that have telomerase expression and full regenerative potential do not age Humans have aera ct emote 0 only early in development at, bray, spinal cov aul in bbls brah) ni Se stscien sma _ Bee tnat a pcm Ss Yee ties r — gaia Int J. Mol. Sci. 2015, 16, 25392-25432 = BIOTIME
Slide 16: BioTime
BIOTIME KD (6424 19-8109 Sa) (98) 19 1 (93) 09-8809 sat (8) 09 a) 80 —— | iN —— § 8 SS ——— i) & [) ¢ i) Is = 3 (=) o i o oO oc = Ss © e ie) a a I= 6 x lu fa <x
Slide 17: The Market
The Market Aging: The demographic trend of our time U.S. Bureau of the Census + 80% of $2.5T health care costs associated with chronic disease. - Four chronic diseases: heart, cancer, stroke, and diabetes cause 2/3 deaths in U.S. BIOTIME
Slide 18: The Market
The Market Aging: The demographic trend of our time The Obsession With 'Curing'’ Aging Is Now Big Business ty Laer herent) MARCH 7,208, 620M ET Fortune.com BIOTIME
Slide 19: Powerful technology to address aging
+ Powerful technology to address aging: The demographic trend of our time * Goal: to unlock shareholder value for BTX non-core assets * Three therapeutic programs with potential to address large causes of mortality in U.S. — 12D/Obesity: One of the largest and fastest growing markets with AGEX- BAT1